Allhat: Still providing correct answers after 7 years

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 355-365

  Einhorn, Paula T ^a   Davis, Barry R ^b   Wright Jr , Jackson T ^c   Rahman, Mahboob ^c   Whelton, Paul K ^d   Pressel, Sara L ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; alpha blockers; antihypertensive therapy; calcium channel blockers; diuretics; thiazides

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT OUTCOME; VALIDATION PROCESS;

ADRENERGIC ALPHA-ANTAGONISTS; AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; HEART FAILURE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SODIUM CHLORIDE SYMPORTER INHIBITORS; UNITED STATES;

EID: 77953808223     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833a8828     Document Type: Review

References (68)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
3. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003; 42:239-246.
4. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003; 42:1206-1252.
6. Muntner P, Krousel-Wood M, Hyre AD, et al. Antihypertensive prescriptions for newly treated patients before and after the main Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines. Hypertension 2009; 53:617-623.
7. Feldman RD, McAlister FA. Postgame wrap of the ultimate blood pressure megatrial: did it score an ALLHAT trick or was it 'three strikes and you're out?'. Hypertension 2009; 53:595-597.
8. Bartholomew LK, Cushman WC, Cutler JA, et al. Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clin Trials 2009; 6:329-343.
9. Stafford R, Bartholomew L, Cushman W, et al. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med 2010; 170:851-858.
10. Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens 2003; 5:9-13.
11. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med 2003; 139:777-780.
12. Zanchetti A, Mancia G. The ALLHAT trial: a verdict or a challenge? J Hypertens 2003; 21:223.
13. Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ 2003; 326:1156-1157.
14. Davis BR, Furberg CD, Wright JT Jr, et al., ALLHAT Collaborative Research Group. ALLHAT: setting the record straight. Ann Intern Med 2004; 141:39-46.
15. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin- converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
16. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
17. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
18. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
19. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
20. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
21. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419.
22. Rahman M, Brown CD, Coresh J, et al. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 2004; 164:969-976.
23. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:936-946.
24. Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144:172-180.
25. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31:353-360.
26. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008; 168:207-217.
27. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:1401-1409.
28. Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens 2004; 6:116-125.
29. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191-2201.
30. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293:1595-1608.
31. Davis BR, Piller LB, Cutler JA, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006; 113:2201-2210.
32. Einhorn PT, Davis BR, Massie BM, et al. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J 2007; 153:42-53.
33. Grimm RH, Davis BR, Piller LB, et al. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? J Clin Hypertens (Greenwich) 2009; 11:466-474.
34. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive And Lipid- Lowering Treatment To Prevent Heart Attack Trial. Circulation 2008; 118:2259-2267.
35. Margolis KL, Dunn K, Simpson LM, et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and nonblack patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Am Heart J 2009; 158:948-955.
36. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54:2023-2031.
37. Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2008; 10:751-760.
38. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832-842.
39. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
40. Hypertension Detection and Follow-up Program Cooperative Group. Fiveyear findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242:2562-2571.
41. Hypertension Detection and Follow-up Program Cooperative Group. Fiveyear findings of the Hypertension Detection and Follow-Up Program. II. Mortality by race-sex and age. JAMA 1979; 242:2572-2577.
42. Kostis JB, Davis BR, Cutler J, et al., for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278:212-216.
43. Davis BR, Cutler JA, Gordon DJ, et al., for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-360.
44. Neaton JD, Kuller LH. Diuretics are color blind. JAMA 2005; 293:1663-1666.
45. Einhorn PT. National Heart, Lung, and Blood Institute-initiated program 'Interventions to Improve Hypertension Control Rates in African Americans': background and implementation. Circ Cardiovasc Qual Outcomes 2009; 2:236-240.
46. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52:818-827.
47. Yu W, Ash AS, Levinsky NG, Moskowitz MA. Intensive care unit use and mortality in the elderly. J Gen Internal Med 2000; 15:97-102.
48. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119:3070-3077.
49. Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: a community perspective. Circ Heart Failure 2008; 1:91-97.
50. Shotan A, Garty M, Blondhein DS, et al. Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from Heart Failure Survey in Israel (HFSIS). Eur Heart J 2010; 31:309-317.
51. Sjoholm A. ALLHAT: a critical assessment. Blood Press 2004; 13:75-79.
52. Unger T. Lessons from ALLHAT. Are low budget diuretics first line therapy in hypertension? Z Kardiol 2004; 93:349-356.
53. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293-302.
54. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327:685-691.
55. Yusuf S, Sleight P, Pogue J, et al., for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153. (Pubitemid 30051645)
56. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
57. Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002; 137:313-320.
58. Pitt B. The role of chlorthalidone in patients with high-risk hypertension. J Clin Hypertens (Greenwich) 2009; 11:460-461.
59. Massie BM. Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective. J Clin Hypertens (Greenwich) 2009; 11:462-465.
60. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138:542-549.
61. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
62. Agodoa LY, Appel L, Bakris GL, African American Study of Kidney Disease and Hypertension (AASK) Study Group et al.. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719-2728.
63. Guideline 7: pharmacological therapy: use of antihypertensive agents in CKD. Available at: http://www.kidney.org/professionals/KDOQI/guidelines-bp/ guide-7.htm [Accessed 10 February 2010].
64. Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25:1311-1317.
65. Carter BL, Einhorn PT, Brands M, et al., Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008; 52:30-36.
66. Mendoza MD, Stevermer JJ. Hypertension with metabolic syndrome: think thiazides are old hat? ALLHAT says think again. J Fam Pract 2008; 57:306-310.
67. Zanchetti A, Mancia G, Black HR, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009; 27:673-679.
68. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361:2153-2164.